Skip to main content
. 2021 Oct 9;13(10):1649. doi: 10.3390/pharmaceutics13101649

Table 2.

Comparison of the viral vectors in clinical trials: AAV, LV, and AV.

Vector Type Package Limitation Superiority Deficiency References
AAV 4.5 kb low immunogenicity, serotype-related targeting, stable transgene expression low packaging capacity [32]
LV 8 kb large packaging capacity, low cell cycle tendency long lasting expression of Cas9 [33]
AV >8 kb large packaging capacity, no-integration to host genome high immunogenicity [17]